AbbVie Inc. ABBV
NYSE · XNYS · stock
Chart by TradingView
7/9
Piotroski F — financial health
-0.34
Altman Z″ — distress risk · distress
275.8%
Dividend payout · at-risk
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $61.2B | $4.2B | — | $17.8B | -$3.3B |
| 2024 | $56.3B | $4.3B | — | $17.8B | $3.4B |
| 2023 | $54.3B | $4.9B | — | $22.1B | $10.4B |
| 2022 | $58.1B | $11.8B | — | $24.2B | $17.3B |
| 2021 | $56.2B | $11.5B | — | $22.0B | $15.4B |
| 2020 | $45.8B | $4.6B | — | $16.8B | $13.1B |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.34 (distress)
- Working capital / assets -0.106
- Retained earnings / assets -0.116
- EBIT / assets 0.113
- Equity / liabilities -0.024
Source: SEC EDGAR filings · CIK 0001551152 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.